Portolan Capital Management, LLC Candel Therapeutics, Inc. Transaction History
Portolan Capital Management, LLC
- $1.22 Billion
- Q1 2025
A detailed history of Portolan Capital Management, LLC transactions in Candel Therapeutics, Inc. stock. As of the latest transaction made, Portolan Capital Management, LLC holds 881,184 shares of CADL stock, worth $5.83 Million. This represents 0.41% of its overall portfolio holdings.
Number of Shares
881,184
Previous 753,745
16.91%
Holding current value
$5.83 Million
Previous $6.54 Million
23.91%
% of portfolio
0.41%
Previous 0.5%
Shares
2 transactions
Others Institutions Holding CADL
# of Institutions
86Shares Held
15.4MCall Options Held
536KPut Options Held
335K-
Baker Bros. Advisors LP New York, NY2.44MShares$16.1 Million0.16% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.15MShares$14.2 Million8.46% of portfolio
-
Northpond Ventures, LLC1.94MShares$12.8 Million48.35% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.74MShares$11.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY823KShares$5.45 Million0.0% of portfolio
About Candel Therapeutics, Inc.
- Ticker CADL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,891,900
- Market Cap $191M
- Description
- Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the...